Bicycle Therapeutics Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics or view top-rated stocks.

Wall Street analysts have given Bicycle Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bicycle Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Bicycle Therapeutics.

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.52). The firm earned $3.84 million during the quarter, compared to analyst estimates of $1.05 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 42.73% and a negative net margin of 321.26%.
View Bicycle Therapeutics' earnings history.

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BCYC shares have increased by 35.1% and is now trading at $23.92.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1 year price objectives for Bicycle Therapeutics' stock. Their forecasts range from $25.00 to $58.00. On average, they expect Bicycle Therapeutics' stock price to reach $38.00 in the next year. This suggests a possible upside of 58.9% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bicycle Therapeutics include Myovant Sciences (MYOV), Kura Oncology (KURA), Revance Therapeutics (RVNC), Madrigal Pharmaceuticals (MDGL), Harmony Biosciences (HRMY), Generation Bio (GBIO), Stoke Therapeutics (STOK), ImmunoGen (IMGN), NGM Biopharmaceuticals (NGM), Pandion Therapeutics (PAND), Seres Therapeutics (MCRB), Zentalis Pharmaceuticals (ZNTL), Aurinia Pharmaceuticals (AUPH), Ironwood Pharmaceuticals (IRWD) and Organogenesis (ORGO).
View all of BCYC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Bicycle Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atlas Venture Advisors Inc. (3.46%), Victory Capital Management Inc. (0.96%), Renaissance Technologies LLC (0.46%), Verition Fund Management LLC (0.19%), Bank of New York Mellon Corp (0.07%) and US Bancorp DE (0.07%). Company insiders that own Bicycle Therapeutics stock include Deborah Harland, Kevin Lee, Lee Kalowski, Life Sciences Fund V Lp Sv and Plc Glaxosmithkline.
View institutional ownership trends for Bicycle Therapeutics.

BCYC stock was sold by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc.. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kevin Lee, Lee Kalowski, and Plc Glaxosmithkline.
View insider buying and selling activity for Bicycle Therapeutics or view top insider-selling stocks.

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Victory Capital Management Inc., Bank of New York Mellon Corp, US Bancorp DE, Captrust Financial Advisors, and Verition Fund Management LLC. Company insiders that have bought Bicycle Therapeutics stock in the last two years include Deborah Harland, and Life Sciences Fund V Lp Sv.
View insider buying and selling activity for Bicycle Therapeutics or or view top insider-buying stocks.

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCYC stock can currently be purchased for approximately $23.92.

Bicycle Therapeutics has a market capitalization of $509.62 million and generates $13.80 million in revenue each year. The company earns $-30,610,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

Bicycle Therapeutics employs 81 workers across the globe.

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.